Oral semaglutide vs DPP-4i on body weight in Japanese people with type 2 diabetes
Not Applicable
Recruiting
- Conditions
- Type 2 diabetes
- Registration Number
- JPRN-UMIN000051448
- Lead Sponsor
- Dokkyo Medical University Department of Endocrinology and Metabolism
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 70
Inclusion Criteria
Not provided
Exclusion Criteria
1)Type 1 diabetes 2)Liver dysfunction (hepatic enzymes more than three times the upper limit of normal ranges) 3)A pregnant woman and/or a woman under breast-feeding 4)Impaired kidney function (serum crearinine greater than 1.3 mg/dl in men, 1.2 mg/dl in women) 5)Diabetic proliferative retinopathy 6)The patients who has an anamnesis of hypersensitivity to the ingredient of a trial drug 7)No treatment with other GLP-1R analogue 8)Patient with intolerance of medical reasons by doctor.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Weight change after 24 weeks
- Secondary Outcome Measures
Name Time Method Changes in HbA1c, urinary albumin (UACR), and blood pressure after 24 weeks BNP, body composition, electrocardiogram (CVR-R), serum HMV adiponectin, serum sDPP-4 (sCD26), DTBQ score changes PAI-1, TAT, PIC, insulin, C-peptide, glucagon, blood amino acid fraction